Geert Maertens joined Biocartis in 2009 as Chief Scientific Officer. He plays an important role in assay pipeline development and external research collaborations in major fields such as cancer and infectious, neurological, genetic and metabolic diseases.
Geert started his career at Innogenetics in 1990, where he initiated the hepatitis-Cprogram. He was head of the company’s Infectious Diseases Business Unit, which developed and marketed >20 diagnostic assays for HIV, HBV, HCV and bacterial typing and resistance during his tenure. Geert was put in charge of HBV, HCV, and HPV vaccine and mAb development in 2002. With the incorporation of GENimmune as a therapeutic vaccines specialty subsidiary of Innogenetics in September 2007, he became Vice President Corporate Development, a post he held until 2008.
